research The ATP sensitive potassium channel (KATP) is a novel target for migraine drug development
This review suggests that blocking the ATP-sensitive potassium (K ATP) channel, particularly the Kir6.1/SUR2B subtype, may prove effective in treating migraines, with preclinical data supporting this approach; however, human studies are absent, and potential side effects could complicate clinical use.